NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 81 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q1 2015. The put-call ratio across all filers is 67.56 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,000 | 0.0% | 10,000 | 0.0% | 0.00% | – |
| Q4 2018 | $1,000 | -50.0% | 10,000 | 0.0% | 0.00% | – |
| Q3 2018 | $2,000 | 0.0% | 10,000 | 0.0% | 0.00% | – |
| Q2 2018 | $2,000 | -50.0% | 10,000 | 0.0% | 0.00% | – |
| Q1 2018 | $4,000 | 0.0% | 10,000 | 0.0% | 0.00% | – |
| Q4 2017 | $4,000 | 0.0% | 10,000 | 0.0% | 0.00% | – |
| Q3 2017 | $4,000 | -20.0% | 10,000 | 0.0% | 0.00% | – |
| Q2 2017 | $5,000 | -16.7% | 10,000 | 0.0% | 0.00% | – |
| Q1 2017 | $6,000 | 0.0% | 10,000 | 0.0% | 0.00% | -100.0% |
| Q4 2016 | $6,000 | -33.3% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $9,000 | +80.0% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $5,000 | -44.4% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $9,000 | -60.9% | 10,000 | 0.0% | 0.00% | -75.0% |
| Q3 2015 | $23,000 | +43.8% | 10,000 | 0.0% | 0.00% | +100.0% |
| Q2 2015 | $16,000 | 0.0% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $16,000 | -15.8% | 10,000 | 0.0% | 0.00% | -33.3% |
| Q4 2014 | $19,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 15,575,946 | $14,711,000 | 89.51% |
| Financial Advisory Group | 10,000 | $356,000 | 0.17% |
| COMMERZBANK AKTIENGESELLSCHAFT /FI | 6,704,067 | $6,332,000 | 0.05% |
| LifePlan Financial Group, Inc | 28,810 | $27,000 | 0.02% |
| Greenwich Wealth Management LLC | 65,066 | $61,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 649,880 | $614,000 | 0.01% |
| LYNCH & ASSOCIATES/IN | 18,000 | $17,000 | 0.01% |
| SII INVESTMENTS INC/WI | 90,315 | $86,000 | 0.01% |
| Stratos Wealth Partners, LTD. | 42,535 | $40,000 | 0.00% |
| SVB WEALTH LLC | 46,262 | $44,000 | 0.00% |